drugset
drugset / Trial / NCT04673799

Comparing of the Pharmacokinetics, Immunogenicity and Safety of MV088 and Prolia® in Healthy Adults.

NCT04673799 ↗

Phase 1 Unknown 144 enrolled Kunming Pharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

A Randomized, Double-blind and Parallel Group Study to Compare the Pharmacokinetics, Immunogenicity and Safety of MV088 and Prolia® in Healthy Adults.

Timeline

Start
2021-02-22
Primary completion
2021-10-18
Completion
2021-10-18

Drugs

EvaluationDrugModalityDoseRoute
Comparator Denosumab Monoclonal antibody 60 mg Subcutaneous
Subject MV088 Unknown 60 mg Subcutaneous

Indications

No indication recorded.